Want to see HK:0911 full AI Analyst Report?
0911 Stock Chart & Stats
HK$0.28
-HK$0.03(-8.77%)
At close: 4:00 PM EST
HK$0.28
-HK$0.03(-8.77%)
Day’s Range― - ―
52-Week RangeHK$0.24 - HK$1.40
Previous CloseN/A
Volume500.00
Average Volume (3M)79.14K
Market Cap
HK$66.08M
Enterprise ValueHK$90.67
Total Cash (Recent Filing)HK$17.88M
Total Debt (Recent Filing)HK$107.00K
Price to Earnings (P/E)15.0
Beta-0.18
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield121.95%
Share Statistics
EPS (TTM)0.02
Shares Outstanding169,445,000
10 Day Avg. Volume79,397
30 Day Avg. Volume79,141
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.12
Price to Sales (P/S)0.07
P/FCF Ratio1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Minimal LeverageExtremely low leverage gives the company substantial financial resilience and reduces interest and refinancing pressure. This conservative capital structure preserves flexibility to fund operations, absorb weaker periods, and pursue growth without relying heavily on additional borrowing.
Improved Cash GenerationThe sharp improvement in operating and free cash flow indicates that the recent return to profitability is translating into internally generated funds. Stronger cash conversion can support reinvestment and liquidity, although the longer history still warrants attention to consistency.
Profitability TurnaroundThe return to positive operating profit and net income marks a meaningful recovery from the large losses recorded in 2022–2023. Combined with the 2025 revenue rebound, this improves the company’s operating base and creates potential for further earnings recovery if execution holds.
Bears Say
Very Thin MarginsVery thin gross and net margins leave limited protection against pricing pressure, cost increases, or weaker product mix. The decline from 2024 levels also suggests that the turnaround remains fragile, with relatively small operating changes capable of materially affecting earnings.
Volatile Revenue HistoryThe conflicting multi-period pattern of contraction followed by a sharp rebound points to uneven revenue durability rather than a consistently expanding base. Such volatility can make planning, resource allocation, and margin management more difficult over the next several reporting periods.
Low Capital EfficiencyPositive ROE is an improvement, but a level near 1.5% indicates that the substantial equity base is generating limited returns. This constrains the evidence for efficient capital deployment and means stronger earnings growth is needed to demonstrate a durable improvement in shareholder value creation.
Qianhai Health Holdings Ltd. News
0911 FAQ
What was Qianhai Health Holdings Ltd.’s price range in the past 12 months?
Qianhai Health Holdings Ltd. lowest stock price was HK$0.24 and its highest was HK$1.40 in the past 12 months.
What is Qianhai Health Holdings Ltd.’s market cap?
Qianhai Health Holdings Ltd.’s market cap is HK$66.08M.
When is Qianhai Health Holdings Ltd.’s upcoming earnings report date?
Qianhai Health Holdings Ltd.’s upcoming earnings report date is Apr 01, 2027 which is in 191 days.
How were Qianhai Health Holdings Ltd.’s earnings last quarter?
Qianhai Health Holdings Ltd. released its earnings results on Aug 12, 2026. The company reported HK$0.017 earnings per share for the quarter.
Is Qianhai Health Holdings Ltd. overvalued?
According to Wall Street analysts Qianhai Health Holdings Ltd.’s price is currently Overvalued.
Does Qianhai Health Holdings Ltd. pay dividends?
Qianhai Health Holdings Ltd. pays a Notavailable dividend of HK$0.1 which represents an annual dividend yield of 121.95%. See more information on Qianhai Health Holdings Ltd. dividends here
What is Qianhai Health Holdings Ltd.’s EPS estimate?
Qianhai Health Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Qianhai Health Holdings Ltd. have?
Qianhai Health Holdings Ltd. has 169,445,000 shares outstanding.
What happened to Qianhai Health Holdings Ltd.’s price movement after its last earnings report?
Qianhai Health Holdings Ltd. reported an EPS of HK$0.017 in its last earnings report. Following the earnings report the stock price went up 1.818%.
Which hedge fund is a major shareholder of Qianhai Health Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:0911
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Qianhai Health Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
30.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
12.50%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Qianhai Health Holdings Ltd.
Qianhai Health Holdings Limited (0911.HK) functions as an investment holding company primarily focused on the distribution of health products and electronic components within Hong Kong. Its operations are structured into two main divisions: Health-Care Products and Electronic Component Products. The Health-Care Products segment supplies a range of items, including Chinese herbal medicines, various skincare and wellness products, and American ginseng, catering to both wholesale and retail clients. Concurrently, the Electronic Component Products division deals in items such as central processing units (CPUs) and semiconductors. Beyond these primary sales, the company also engages in the trading of both its health-care and electronic component offerings, alongside a money lending business. Established in 1989, the company underwent a name change in September 2016 from its previous identity, Hang Fat Ginseng Holdings Company Limited. It is headquartered in Sheung Wan, Hong Kong, and operates as a subsidiary of Explorer Rosy Limited.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Tianda Pharmaceuticals Ltd.
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Jacobson Pharma Corporation Limited
―